Dihydralazine is a prescription drug with antihypertensive properties. It functions by combating the effects of adrenaline, and by expanding the blood vessels so as to enable smoother flow of blood by decreasing the pressure. It is generally administered orally as tablet formulations and, when rapid control is required, parenteral formulations may be used under clinical supervision. Pharmacologically it acts primarily as a direct arteriolar vasodilator, lowering systemic vascular resistance and afterload; this results in decreased blood pressure and compensatory increases in heart rate and cardiac output in some patients. The compound undergoes hepatic biotransformation, including N acetylation pathways common to hydrazine class agents, with renal excretion of metabolites. Quality control for active pharmaceutical ingredient and finished product relies on validated assays such as HPLC and LC MS for assay, related substances, and degradation profiling, and therapeutic use requires prescription and monitoring for hemodynamic response and known class adverse effects.
Parent: Dihydralazine
Impurities encountered during manufacture and storage include process related precursors and intermediates derived from phthalazine ring chemistry, hydrazine containing species, partially reduced or oxidized phthalazine derivatives, and trace solvent residues; degradation impurities can form under oxidative or acidic conditions. Typical analytical acceptance criteria used in regulatory filings and internal quality specifications often reflect the following example limits: specified related compounds individually not greater than 0.2 percent, unspecified individual impurities not greater than 0.10 to 0.15 percent, and total impurities not greater than 0.5 percent. Identification and control of impurities follow ICH Q3A and Q3B principles with reporting, identification, and qualification thresholds adjusted to the maximum daily dose and specific regulatory requirements; final limits should be those established in the product monograph or regulatory submission for the marketed batch.
Dihydralazine tablets are used to lower elevated blood pressure as part of the management of hypertension; they are typically used when a direct arteriolar vasodilator is indicated and are prescribed together with monitoring and adjunct therapy as appropriate.
They are related chemically and share antihypertensive activity, but they are distinct compounds with different chemical structures and potentially different pharmacokinetic profiles; they are not automatically interchangeable without clinician guidance.
There is no single universal brand name for dihydralazine sulfate 25 mg that applies in all markets; the product is often marketed as a generic under the active ingredient name and specific brand names vary by country and manufacturer, so consult local formularies or the product label.
Dihydralazine belongs to the antihypertensive class of direct arteriolar vasodilators and is chemically classified within the hydrazinophthalazine derivatives.
